These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 30715686)

  • 21. A Prospective, non-intErventional Registry Study of PatiEnts initiating a Course of drug Therapy for overactIVE bladder (PERSPECTIVE): Rationale, design, and methodology.
    Rovner ES; Carlson KV; Deal AS; Nair KV; Oakkar EE; Park J; Gemmen E; Kristy RM; Gooch KL; Schermer CR
    Contemp Clin Trials; 2018 Jul; 70():83-87. PubMed ID: 29777865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. No. 353-Treatments for Overactive Bladder: Focus on Pharmacotherapy - An Addendum.
    Geoffrion R
    J Obstet Gynaecol Can; 2017 Dec; 39(12):1221-1229. PubMed ID: 28986184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validation of overactive bladder questionnaire (1-week recall version) in medically complex elderly patients with overactive bladder.
    Barsdorf AI; Carlsson M; Bushmakin AG; Quinn S; Cappelleri JC; Pleil A
    Int Urogynecol J; 2017 Dec; 28(12):1857-1863. PubMed ID: 28378111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain.
    Nazir J; Hakimi Z; Guelfucci F; Khemiri A; Fatoye F; Blázquez AMM; González MH
    BMC Urol; 2018 Sep; 18(1):76. PubMed ID: 30180826
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
    Chen HL; Chen TC; Chang HM; Juan YS; Huang WH; Pan HF; Chang YC; Wu CM; Wang YL; Lee HY
    World J Urol; 2018 Aug; 36(8):1285-1297. PubMed ID: 29556972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.
    Maman K; Aballea S; Nazir J; Desroziers K; Neine ME; Siddiqui E; Odeyemi I; Hakimi Z
    Eur Urol; 2014 Apr; 65(4):755-65. PubMed ID: 24275310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Developments in the medical treatment of overactive bladder].
    Alcántara Montero A
    Semergen; 2016; 42(8):557-565. PubMed ID: 26671329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Overactive Bladder Step Therapy Policies on Medication Utilization and Expenditures Among Treated Medicare Members.
    Abbass IM; Caplan EO; Ng DB; Kristy R; Schermer CR; Bradt P; Collins JM; Chan WM; Suehs BT
    J Manag Care Spec Pharm; 2017 Jan; 23(1):27-37. PubMed ID: 28025920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The new era in the pharmacological treatment of overactive bladder (OAB): mirabegron--a new selective beta3agonist].
    Rechberger T; Kulik-Rechberger B; Miotła P; Wróbel A
    Ginekol Pol; 2014 Mar; 85(3):214-9. PubMed ID: 24783434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Indirect treatment comparison (ITC) of medical therapies for an overactive bladder.
    Obloza A; Kirby J; Yates D; Toozs-Hobson P
    Neurourol Urodyn; 2017 Sep; 36(7):1824-1831. PubMed ID: 28220521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mirabegron: a Beta-3 agonist for overactive bladder.
    Bragg R; Hebel D; Vouri SM; Pitlick JM
    Consult Pharm; 2014 Dec; 29(12):823-37. PubMed ID: 25521658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study).
    Staskin D; Herschorn S; Fialkov J; Tu LM; Walsh T; Schermer CR
    Int Urogynecol J; 2018 Feb; 29(2):273-283. PubMed ID: 28620791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?
    Kobayashi M; Nukui A; Kamai T
    Low Urin Tract Symptoms; 2018 May; 10(2):158-166. PubMed ID: 28009939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mirabegron: A Review in Overactive Bladder Syndrome.
    Deeks ED
    Drugs; 2018 Jun; 78(8):833-844. PubMed ID: 29869204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence available on the use of the selective β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder.
    Angulo JC; Khullar V; Nitti VW; Siddiqui E
    Actas Urol Esp; 2013; 37(10):640-51. PubMed ID: 23850394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overactive bladder medication: Persistence, drug switching, and reinitiation.
    Soda T; Tashiro Y; Koike S; Ikeuchi R; Okada T
    Neurourol Urodyn; 2020 Nov; 39(8):2527-2534. PubMed ID: 32985716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
    Chapple CR; Cardozo L; Nitti VW; Siddiqui E; Michel MC
    Neurourol Urodyn; 2014 Jan; 33(1):17-30. PubMed ID: 24127366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases.
    Chen SF; Kuo HC
    Low Urin Tract Symptoms; 2019 Apr; 11(2):O53-O58. PubMed ID: 29380517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.